PRAX
NASD Praxis Precision Medicines, Inc.$251.38 ↑ +0.00 (+0.00%) Trading Up from the previous close of $251.38, $8.12 below the day’s high of $259.50
- YTD change
- -14.71%
- vs 20-day SMA
- -13.49%
- vs 200-day SMA
- -20.62%
Price ranges
Price & Performance
-65.62 (-20.70%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 72.5% away from all-time highs of $914.26
- PRAX is down 15% since the beginning of the year
- PRAX is up 372% over the past 12 months
- PRAX is down 25% over the past 1 month
- 14% of all PRAX investors are betting against PRAX
PRAX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +380.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.08
- Last 5 days
- -14.93%
- vs 8-day SMA
- -10.17%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
